Several polypeptide hormones have been isolated in pure state from hypothalamic tissue. These hypothalamic hormones stimulate or inhibit the release of pituitary hormones. The determination oftheir primary structure was followed by large scale synthesis and extensive physiological, clinical and veterinary studics on natural and synthetic hormones as weil as their synthetic analogues. Thc tripeptide (pyro)Glu-His-Pro-NH 2 (TRH) stimulates the relcase of thyrotropin and prolactin in laboratory and domestic animals and humans and can be used clinically for diagnostic tests. The tripeptide Pro-Leu-Gly-NH 2 (MIF) inhibits the release of melanocyte stimulating hormone ( MSH) in frogs and may have direct effects upon the brain. Further work is needed for the isolation and determination of structure of physiological growth hormonereleasing hormone. which would be of major clinical valuc. The structure of prolactin release-inhibiting factor (PIF) has not yet been elucidated. The decapeptide (pyro)Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH 2 (LH-RH) stimulates the release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH) in rats, hamsters, rabbits, sheep, pigs. cattle, monkeys, chickens and humans, but whether this decapeptide is also the physiological FSH-RH, remains to be established. LH-RH/FSH-RH also stimulates biosynthesis of LH and FSH in rats and induces ovulation in rats, rabbits, hamsters, sheep and women. LH-RH/FSH-RH stimulatcs spermatogenesis in rats. and based on preliminary results. also in men. Sex steroids appear to be responsible in part for the preferential release of LH and FSH in response to LH-RH/FSH-RH. Examination of the biological properties of a large num her of decapeptide analogues ofLH-RH/FSH-RH shows that (pyro )Glu, His and Trp residues may be necessary for the release of LH and FSH. Analogues of LH-RH in which other aminoacidssuch as Tyr, Ser, Arg and Leu have been replaced still possess major biological activity, suggesting that these amino acids may be required only for binding to receptors. There has been no dissociation ofLH-RH activity from FSH-RH activity in any of the analogues examined. Tripeptide to nonapeptide analogues of LH-RH have little, if any, activity. The synthesis of a competitive analogue of LH-RH/FSH-RH could Iead to the development of new methods of birth control. Another such approach could be obtained eventually by the use of antisera to LH-RH.
The existence of hypothalamic substances regulating anterior pituitary gland was postulated many years ago 1 • However, it is only during the past few years that sufficient progress has been made to prove this concept and establish the practical significance of hypothalamic hormones. The isolation. determination of structure. and synthesis of several hypothalamic hormones have been accomplished and these hormones are being evaluated now for diagnostic and therapeutic uses. It is likely that additional hypothalamic hormones will be structurally identified and synthesized during the next few years. Thus, through hypothalamic hormones, we may be able one day eventually to exert complete control over much of the endocrine system.
Because the hypothalamus is the part of the brain nearest to the pituitary gland. it was reasonable to postulate that neural components were involved in the control of the secretion of the pituitary hormones. The median eminence. the part ofthe hypothalamus closest to the pituitary. is connected to the pituitary by means ofa stalk. Harris 1 suggested that a portal system ofblood vessels hetween the median eminence and pituitary is the pathway for the hypothalamic regulation of pituitary function 1 • After cutting the portal blood vessels between the hypothalamus and pituitary. changes occurred in the function of the endocrine glands (ovary, testis. adrenal cortex and thyroid) acted upon by anterior pituitary hormones. The best explanation ofthe relationship between the portal blood supply and anterior pituitary function was that hypothalamic nerve fibres liberate hormonal substances into the capillaries in the median eminence, and then these substances are carried by the portal vessels to the pituitary gland where they stimulate or inhibit the release of various anterior pituitary hormones 1 . Direct evidence for the existence of specific hypothalamic neurohormones involved in the release of anterior pituitary hormoneswas lacking for many years. Demonstration of the existence of a corticotropinreleasing factor by Saffran and Schally in 1955 2 opened the way for subsequent discoveries of other hypothalamic regulatory substances. The existence of at least nine hypothalamic hormones regulating the pituitary gland is now reasonably weil established ( Table 1) . The abbreviation -RH could represent releasing hormone or regulating hormone, since some hypothalamic hormones appear to affect the synthesis 316
as weil as release of respective anterior pituitary hormones. F or three pituitary hormones, there is a dual system of hypothalamic controt one system being inhibitory and one being stimulatory. The existence of hypothalamic inhibitors, as well as stimulators of growth hormone, prolactin and melanocytestimulating hormone may be explained by the absence of negative feedback products from their target tissues. In the case of corticotropin. thyrotropin, luteinizing hormone and follicle-stimulating hormones, hormones (corticosteroids, thyroid hormones and sex steroids) from the target glands inhibit secretion of these anterior pituitary hormones by negative feedback action exerted on the pituitary, hypothalamus or both 3 . Before describing in detail the most recent physiological, biochemical and clinical findings relating to each of the known hypothalamic hormoncs, we would like to present some general information about these hormones which may be of particular interest to chemists.
These hypothalamic hormones are polypeptides and appear tobe present in the hypothalamus in microscopic quantities, e.g. in the case of the LHreleasing hormone (LH-RH1 its content is about 50 nanogrammes per one pig or sheep hypothalamus. Consequently, large quantities of hypothalami amounting to 250000-1 000000 or more fragments have to be used for purification. Because of the instability of some hypothalamic hormones. especially CRH, as weil as the presence of hundreds or thousands of other peptides in the hypothalamic tissue, the mostmodern methods of protein and peptide chemistry are used for the purification. Frequently, even a maximal recovery of activity may not yield enough material for structural work. Thc latter was carried out by conventional methods but on a micro-scale and was based on the Edman-Dansyl stepwise degradation, occasionally supplemented by mass spectroscopy and selective tritiation of the C-tcrminus 4 . The syntheses were carried out by solid-phase as well as classical methods. Natural and synthetic hypothalamic hormones can exert their effects in vivo and in vitro in nanogramme or even picogramme doses, testifying to the extremely high biological activity of these substances. For veterinary use in large domestic animals and for clinical use in human beings for diagnosis and therapy, dosages of a few tens or hundreds of microgrammes are adequate in spite of dilution in general blood circulation after intravenous. intramuscular or subcutaneous administration.
CORTICOTROPIN RELEASING HORMONE (CRHJ
The central nervous system (CNS). and the hypothalamus mediate the response to 'stress'. Thus, external environmental factors. sensory stimuli and emotions can result in the Iiberation of corticotropin-releasing hormone (CRH) which stimulates the release ofadrenocorticotropic hormone (ACTH) from the pituitary. In turn, ACTH augments the secretion by the adrenal cortex of steroids necessary for survival. CRH was the first hypothalamic hormone to be demonstrated by Saffran and Schally 2 , but its instability and the difficulty with its assays have delayed the isolation of adequate amounts for elucidation of its structure. In our early attempts to purify CRF. we utilized posterior pituitary powders, since hypothalami were not readily available. A tentative, partial amino aeirl ~~quenee of a eortieotropin-releasing factor (CRF) purified from powdered ___2Qrcine posterior pituitary tissue was reported 5 as Ae-Ser-Tyr-Cys-Phe~His-[Asp-NH 2 • Glu-NH.:J-Cy~-(Pro. Va))-Lys-Giy-NH2. lt is not known whether the physiological CRH from the hypothalamus is related to the proposed neurohypophysieal CR F. Polypeptides synthesized by eoupling the dipeptides Ser-His or His-Scr to thc free amino-terminal group of Iysine vasoprcssin have some CRF activitl'. Thc clinical usefulness of CRH may bc limited to diagnostic tests.
THYROTROPIN RELEASING HORMONE (TRHJ
Hypothalamie thyrotropin-releasing hormone ITRII) stimulatcs TSH release. and thyroid hormones inhibit it". In 1966 wc rcportcd that porcinc TRH. the first of the hypothalamic hormones to he isolatc(L contained thrce amino acids. histidine. proline and glutamie acid. in equimolar ratios -:_ This eonstituted thc first proofthat hypothalamic hormoncs are polypcptidcs. In subsequent investigations. we determincd the amino aeid scqucncc and the strueture of pareine TRH and aehievcd its synthesisx 1 -~. Thc moleeular strueture of pareine TRH is shown in Fiqure I.
Pro-Nfl.
Fiqure I Molccular structurc of thyrotropin-rclcasing hormonc !"IR III Similar cxperiments conducted by Burgus and co-workcrs estahlishcd that the strueture of ovine TRH was also (pyro )Giu-H is-Pro-amidc 1 
1
. lt is probable that bovine and human TRH have the same strueturc 15 havc bccn confirmed and cxtcndcd hy using synthetie TR H. which has thc samc activity as natural TR 1-1 3 TSH release into the plasma oeeurs when TRH is administercd intravenously, subcutancously. intraperitoncally or orally. In ritro. TRH in picogrammc dose releases TSH from the pituitaries of rats. shccp and goats 3 ;\ doscresponse relationship, both in l'im and in Pitro, is readily dernonstrahle that is. increasing doses of TRH causc a progrcssivcly grcatcr rclcase of TSH. The thyroid hormones thyroxinc ctnd triiodothyroninc can block thc stimu~ latory cffect of TRH by an action excrtcd directly on thc pituitary gland 15 .
Afteradministration of tritiated or 14 C-labelled TR H to rats and mice. thc radioactivity aeeumulates in the pituitary human plasma J<.J is caused mainly by the enzymatic cleavage of the amide group at the prolyl end. The half-life of TRH in the blood of the rat is about four minutes 1 R. Cyclic AMP may be the mediator of the action of TRH on the pituitary cel1 3 . The studies ofthe metabolism, distribution and mechanism of action of TRH have been important because of the increasing use of the hormone. The initial demonstration of the effectiveness of TRH in releasing TSH in human beings was made with a natural preparation of porcine TRH 3 · 15 . The elucidation of the structure and largc scale synthesis of TRH made possible extensive clinical trials with this hormone in many countries in which it was demonstrated that TRH is a powerful safe and nontoxic stimu1ant of TSH release in men, women and children 3 · 15 · 20 . It is also a useful diagnostic compound for testing pituitary TSH reserve and distinguishing pituitary from hypothalamic hypothyroidism. The pattern of rise of TSH in the plasma, after the administration of TRH, may also shed some light on thyroid disease. Recent studies suggest that TRH may relieve some types of mental depression. Synthetic TR H will also release prolactin in sheep, cows and human beings
but it remains tobe established whether TRH is the main prolactin releasing hormonc.
GROWTH HORMONE (GH)-RELEASING HORMONE (GH-RH) AND GROWTH HORMONE-REl.EASE INHIBITING HORMONE (GH-RIH, GIF)
Progress in the Isolation of GH-RH has becn hampered by the difficulty of the methods used for its detection. For following GH -RH activity in the course of its purification. we have conducted tests in vitro and in vivo. The in vitro assay is based on stimulation of release of bioassayable GH 22 from rat pituitaries 23 . The materialstobe tested are added to the incubation medium. For the test in vivo, we use depletion of bioassayable GH in the rat pituitary after intracarotid injcction as an index for GH-RH activity 24 . A decapeptide active in these testsystemswas isolated in pure form from pig hypothalami 25 .
It was structually characterized as Val-His-Leu-Ser-Ala-Glu-Glu-Lys-GluAla26 and synthesized 27 . This amino acid sequence is similar to that of the amino-terminal sequence of the ß-chain or porcine haemoglobin 27 . The pure porcine material and the synthetic decapeptide corresponding structurally to the proposed natural GH-RH were both active in these assay systems in vitro and in vivo.
However. discrepancies between the results obtained by bioassay 22 and radioimmunoassay 28 for GH soon became evident. Preparations ofthe natural porcine decapeptide proposed as GH-RH 25 · 26 , or of the corrcsponding synthetic decapeptide 27 , did not stimulate the release ofimmunoreactivc GH when administered to rats. pigs, sheep, monkeys and menmethyl cellulose (CMC) and countercurrent distribution (CCD). This work confirms the existence of a GH-RH capable of stimulating the release of immunoreactive G H 3 . Further work is needed for the isolation, determination of structure, and synthesis of this GH-RH. This GH-RH might provide a material of possible therapeutic use in inducing normal growth in children and perhaps acting as an anabolic agent free of androgenic effects.
Tests of other partially purified and highly purified fractions of pareine hypothalami revealed the presence of materials capable, in microgramme or nanogramme doses, of inhibiting the release of immunoreactive GH 3 . The existence of a GH release-inhibiting hormone (GH-RIH or GIF) was first suggested by Krulich et al. 29 . lt is likely that many of the problems encountered in the assays for GH-RH were caused by the presence of GH-RH and GIF in the same fractions. The net result was that GIF decreased the stimulation of release of GH or abolished it altogether. Thus, GIF and GH-RH can cancel out their respective effects in some fractions. The detection of GIF in sheep hypothalami can be made more readily, and Brazeau et al. reported the isolation and structure of ovine G IF 30 and its synthesis. The structure of ovine GIF can be seen in Figure 2 . Wehave also synthesized this substance and found it to inhibit GH release in rats, sheep andin men 3 1.
32 .
Pareine hypothalamic extracts appear to contain several substances which inhibit the release of GH 33 and the structure of one of them appears to correspond to ovine GIF. lt is conceivable that GIF could be used in the control of some types of diabetes and perhaps even some pituitary tumours associated with acromegaly. The galactorrhea seen in human patients after surgical cutting of the pituitary stalk or administration of certain tranquillizers may result from removal of the inhibitory influence ofthe hypothalamus on prolactin secretion. Similarly, in rats, transplantation of the pituitary results in increased prolactin secretion 3 . That the inhibition of prolactin se<.:retion in rats is mediated by a hypothalamic substance was first shown by studies conducted in vitro 35 • 36 . Subsequent studies revealed the presence of PRIH or PIF in hypothalamic extracts of sheep, cattle and pigs
37
. We have utilized the techniques of Sephadex gel filtration, chromatography on CMC and CCD for purification of PIF from pig hypothalamic extractions and have obtained it in a virtually homogeneaus state. The structural work is in progress. It is possible that PIF will be of clinical significance in inhibiting undesired lactation. Its possible use for treatment of breast cancer is based only on speculation.
Frequently, the contamination of hypothalamic extracts with prolactinreleasing hormone (PRH) obscures their PIF effect. PRH was thought, at first, to be present only in birrl hypothalami 34 , but recent sturlies inrlicate that hypothalamic extracts of rats anrl pigs contain this activity in arlrlition to PIF 3 . Apart oftbis prolactin-releasing activity can be attributerl to TRH. Synthetic TRH has been shown to stimulate release of prolactin as weil as TSH in rats, human beings, cows anrl sheep 3 · 21 . Nevertheless, TRH may not be the physiological PRH. Recent sturlies inrlicate that purifierl pig hypothalamic fractions, from which TRH was removerl, still stimulate prolactin secretion in vitro, but the structure of PRH is still unknown. The usefulness of TRH in increasing milk prorluction in cows is being evaluaterl.
MElJANOCYTE-STIMULATING HORMONE (MSH)-RELEASING HORMONE (MRH) AND MSH-RELEASE INHIBITING HORMONE (MRIH, MIFJ
Melanocyte-stimulating hormone (MSH) darkens the skin of amphibia, but its role in mammals is not clearly established. The hypothalamus exerts an inhibitory influence upon the release of MSH in lower vertebrates anrl in mammals 3 · 38 . This effect is exerterl by a hypothalamic hormone 3 · 39 . Two peptides with MIF activity were isolated from bovine hypothalami anrl irlentifierl as Pro-Leu-Gly-NH 2 and Pro-His-Phe-Arg-Gly-NH/· 40 • The first of these, which happens to be the carboxyl terminal tripeptirle sidechain of oxytocin, harl greater activity in frogs. Celis et a/. 41 observed that Pro-LeuGly-NH 2 can be formed by incubating oxytocin with an enzyme found in hypothalamic tissue anrl founrl that this compound inhibits MSH release in the rat also. However, Bower and co-workers 42 suggest that tocinoic acid, Cys-Tyr-Ile-Gln-Asn-Cys-OH, the cyclic pentapeptidering of oxytocin, or its amide, tocinamide, is more likely to be MIF.
There is also evirlence for an MSH-releasing hormone (MRH) 39 . lt was suggesterl that the opened NH 2 -terminal ring portion of oxytocin. H-CysTyr-Ile-Gln-Asn-Cys-OH, constitutes MRH 43 . Neither tocinoic acirl nor its rerluced openform has yet been irlentified in hypothalamic tissue. Pro-LeuGly-NH2 has been shown tobe effective in several animal models of Parkinsonism and depression 44 as weil as in a few patients with Parkinson's disease. Further clinical trials with this MIF are in progress.
LUTEINIZING HORMONE AND FOLLICLE STIMULATING HORMONE RELEASING HORMONE (LH-RH/FSH-RH)
It has been known for many centuries that reprorluction is influencerl by seasonal, environmental and emotional factors. Sturlies conrlucted rluring the past 40 years have proved the role of the CNS in the regulation of reprorluctive cycles anrl involvement of the hypothalamus in the control of secretion of the gonadotropins LH and FSH 1 • 3 · 45 . The hypothalamus controls the secretion of LH and FSH from the pituitary and through LH and FSH, regulates ovarian anrl testicular function. In turn. sex hormones ( oestrogen, progesterone anrl testosterone) secreterl by the gonarls. exert a prerlominantly inhibitory feedback action on the hypothalamus anrl the pituitary. In animals, an accurately timerl signal from the brain causes a massive discharge of LH which results in ovulation. This impulse for the 321 discharge of LH is mediated by the LH-releasing hormone (LH-RH) which was first demonstrated in the early 1960s in hypothalamic extracts of rats 46 and subsequently found in similar extracts from domestic animals and human beings 3 . Hypothalamic extracts were also found to contain an FSH-releasing hormone (FSH-RH) 3 · 14 · 45 . Initially, it was thought that LH-RH and FSH-RH activities were due to two different substances. In several laboratories. attempts were made to isolatc both of these substances. Our own efforts were intensified when we demonstrated that highly purified LH-RH of pareine origin unequivocally stimulated both LH and FSH release in men and women under a variety of conditions 3 · 45 . Our work resulted in the isolation from pareine hypothalami of a decapeptide with both LH-RH and FSH-RH activity and the determination of its amino acid composition and sequence 4 7 · 48 · 4 · 49
. The structure of LH-RH is shown in Figure 3 .
This decapeptide was then synthesized 50 . After the announcement of its structure, LH-RH was synthesized by workers in many other laboratories because of its anticipated medical importance 3 · 45 . Assays in our Iabaratory showed that not only the decapeptide synthesized by us but also the LH-RH prcparations made by others according to the structure we proposed Because both natural LH-RH and the synthetic decapeptide corresponding to its structure possessed major FSH-RH as well as LH-RH activity in rats. domestic animals and human beings, we proposed that one hypothalamic hormone. designated LH-RH/FSH-RH, could be responsible for stimulating the release of both FSH and LH from the anterior pituitary gland 3 · 45 . The time courses of the releasc of LH and FSH in vitro. induced by the synthetic or natural hormone, are identical.
Occasional divergence of LH and FSH release in the human menstrual cycle, the oestrous cycle in other animals, and in certain pathological conditions can be explained in part by interactions with sex steroids as oestrogens stimulate LH release and inhibit FSH release in response to LH-RH, and some androgens have the opposite effect. The possibility that another hormone which releases only or predominantly FSH is present in hypothalamic tissue cannot be excluded at present. Nevertheless. the ovulation which can be induced in rats. golden hamsters. rabbits. sheep-'. and amenorrhoeic warnen 51 after treatment with natural and synthetic LH-RH demonstrate that this decapeptide may release enough FSH to cause follicular ovarian maturation. In any case. the detection by radioimmunoassay of a peak of LH-RH during the preovulatory surge of LH and FSH in sheep and women suggests that this decapeptide is most probably the hypothalamic mediator responsible for stimulating the release of the ovulatory quota of LH and FSH 3 . Natural and synthetic LH-RH/FSH-RH can stimulate the synthesis as weil as the release of LH and FSH 52 . This was proved by using modified organ cultures of rat anterior pituitary glands. The addition of nanogrammc amounts of LH-RH to the incubation medium daily for five days augmented the total content of LH and FSH in the stimulated tissue and medium. and increased the incorporation of ~ cn a severe regression of spermatogenesis, but similar rats injected with LH-RH exhibited a striking Stimulation of the spermatogenesis. In hypophysectomized female rats with pituitary grafts, long-tenn treatment with synthetic LH-RH stimulated follicular development 3 • It was demonstrated by electron microscopy that LH-RH induces the extrusion of secretory granules from LH gonadotrophs in rats 3 . The mechanism of action of LH-RH/FSH-RH in inducing LH and FSH release is not known, but cyclic AMP may be the mediator ofthe action of LH-RH on the anterior pituitary 3 . Natural and synthetic preparations of LH-RH/FSH-RH have also been studied in other species of mammals, in chickens and in fish 3 . In golden hamsters, the administration of LH-RH induces ovulation and increases the concentration of LH in the plasma: LH-RH administered to rabbits produces similar effects. When LH-RH is given to sheep, it increases the concentration of LH and FSH in the plasma and induces ovulation in the ewes. Bulls and prepubertal pigs injected with synthetic LH -RH similarly show increased LH concentrations in the plasma. Premature ovulation is also induced in chickens given LH-RH. Sturlies in vivo and in vitro suggest that fish respond to LH-RH. The effect of LH-RH in domestic animals, fish and chickens indicates a possible application of LH-RH/FSH-RH in animal husbandry.
lt is weil documented that LH-RH/FSH-RH of natural or synthetic origin releases LH and FSH in human beings 3 · 45 . Maximum increases in the concentration of LH and FSH in the plasma were observed 15 to 60 minutes after intravenous or subcutaneous injection of LH-RH. It has been shown that LH-RH does not stimulate the release of growth hormone, thyrotropin and ACTH, nor does it inhibit the release of prolactin in rats or humans. In sturlies in Mexico, LH-RH given by intravenous infusion or intramuscularly induced ovulation, confirmed by pregnancy in several women with hypothalamic amenorrhoea 51 • Similar observations were reported from Chile and Germany. This indicates that LH-RH may be useful in the treatment of sterility. Because LH-RH/FSH-RH is active in a nurober of laboratory and domestic animals, primates including man, bird and fish, species specificity probably does not exist for this hormone. The structure of ovine LH-RH was found to be identical tothat of the previously announced porcine hormone 53 . Immunological studies supplemented by physicochemical and bioassay data indicate that bovine, human and rat LH-RH are identical with the porcine and ovine hormone 54 . The use of LH-RH/FSH-RH, its structural analogues, and its other derivatives may Iead to the development of new methods of birth control.
The two main ways in which one could approach the control of fertility would be based on the development of specific antisera capable of neutralizing endogenaus LH-RH and on the synthesis of competitive analogues of LH-RH 3 • 45 . Several types of antisera to LH-RH have been produced recently in rabbits and in guinea-pigs 3 • 54 . Of the male rabbits immunized against LH-RH, those which produced antiborlies to LH-RH developed considerable testicular atrophy. For example, the weight of the two testes of one such rabbit was only 0.3 g, whereas the testes of a control rabbit weighed 5 g. 324
When rabbit antisera to LH-RH were given to female rats on the day of pro-oestrus, ovulation was blocked. These results indicate that antiborlies to LH-RH can bc produced in animals, but the clinical safety of purified animal antisera to LH-RH or of complexes containing conjugated LH-RH and which are uscd for immunizing animals is not known. The antisera to LH-RH have becn used in radioimmunoassays of LH-RH 54 . By means of radioimmunoassays and sturlies with tritium Iabelied LH-RH, the half-life of exogenously administered LH-RH in the rat was measured and was found to bc six to seven minutes. LH-RH administered to man is rapidly degraded in the blood. I ts half-life in man is about four minutes. One of the principal mcchanisms of inactivation of LH-RH in human blood is the cleavage of (pyro)Glu-His from the N-terminus.
The synthesis of a large nurober of structural analogues of LH-RH has helped establish the structure~activity relationship for this hormone The first peptide with higher activity than LH-RH, Des-Gly-10-LH-RHethylamide, was recently synthesized by Fujino et al.~b. It was found tobe two to three times as potent as the parent hormone in releasing LH and FSH in rats, sheep and human beings. The increase in activity can be attributed to replacement of the C-terminal glycine amide of LH-RH by an ethylamide moiety, possibly resulting in an increased affinity for receptor sites, a decrease in enzymatic inactivation, or a combination ofboth factors. Also, replacement of glycine in position 6 by D-alanine increases the LH-RH activity. l\1any modifications abolish LH-RH activity. Thus, most replacements for pyroGlu result in almost complete loss of LH-RH activity. The imidazole ring of His in posititt>n 2 and the indole ring of Trp in position 3 of the peptide appear to be crucial for biological activity and most changes in these positions result in virtually complete loss of LH-RH activity, such analogues having less than one part in 50000 of LH-RH activity of the parent decapeptide. Which amino acids in the LH-RH molecule are involved in binding to the 325 receptors and which exert a functional effect still remains to be confirmed but we conclude that the N-terminal sequence pyroGlu-His-Trp is probably the functional part of the LH-RH molecule and that the remaining amino acids are most likely involved only in binding to receptor sites and/or in transport in blood. One of the analogues, Des-His-2-LH-RH, was reported competitively to antagonize LH-RH in a system in vitro, when present in dosages 10000 times greater than LH-RH 59 . However, this analogue does not inhibit the LH-RH induced stimulation of LH-release in vivo in rats or ovulation in rabbits 3 .
It was decided, nevertheless~ to synthesize the corresponding peptide containing the modified C-terminus 57 . In vivo assays for inhibitory activity of Des-His-2-Des-Gly-10-LH-RH ethylamide revealed that the significant release of LH in rats induced by a standard dose of LH-RH was abolished by prior treatment with 100 Jlg of this peptide antagonist. Later experiments confirmed repeatedly that the peptide inhibits LH release in vivo in doses of 10. 1 and 0.1 ~tg per rat. This is the first peptide which significantly reduced LH secretion in response to LH-RH in vivo. Des-His-2-Des-Gly-10-LH-RH ethylamide has also proved capable, under some conditions. of inhibiting ovulation in both rats and rabbits. This substance represents only an initial member of the first generation of antagonistic LH-RH analogues to have been synthesized, and the chances that morc potent inhibitors of the hormone can be developed now appear more promising. The search for still more effective inhibitors of LH-RH must continue. Irrespective of any possible success in the development of new methods of birth control based on antisera and competitive analogues of LH-RH/FSH-RH, the available results indicate that LH-RH/FSH-RH should find diagnostic and therapeutic application in clinical medicine and that it may be useful also for stimulation of fertility in domestic animals. CONCLUSION A family of polypeptidesexist in the hypothalami of animals and human beings which specifically stimulate or inhibit the release ofpituitary hormones. Several ofthese have been isolated from hypothalamic tissue. Their structures have been elucidated and their syntheses performed. These substances have already been used in the diagnosisand treatment ofvarious clinical conditions. Such compounds, as weil as their analogues and antisera should open new approaches to the veterinarian and physician.
